News / Events

Zolgensma Proposed to Cost 167 Million Yen in Japan

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Pricing & Reimbursement | Keywords: #chuikyo #genetherapy #listing #mhlw #nhi #novartis #pediatrics PRICENTRIC BRIEF: Japanese media have reported that the price of Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec) is expected to be 167 million yen under the National Health Insurance (NHI) scheme In the case of Zolgensma, health official insiders from the MHLW suggested that the […]

Italy’s Oncological Association Seeks to Reduce Cost of CAR-T Cells

Country: ITALY | Region: EUROPE | Type: Policy | Keywords: #alleanzaagainstcancer #car-t #oncology PRICENTRIC BRIEF: Italy’s oncological association, Alleanza Against Cancer (ACC), is seeking to collaborate with the pharma industry in order to implement production capacities and harmonize and automate processes, thus reducing costs related to the manufacture of CAR-T cells The ACC’s statement said, “Indeed, a potential virtuous synergy between academic institutions and pharmaceutical industries […]

EMA Recommends Expanded Remdesivir Compassionate Use Scheme

Country: NETHERLANDS | Region: EUROPE | Type: Regulation | Keywords: #chmp #compassionateuse #covid-19 #ema #gilead #remdesivir PRICENTRIC BRIEF: The European Medicines Agency’s (EMA) human medicines committee, CHMP has recommended expanding the compassionate use scheme for Gilead’s remdesivir to allow more patients with severe COVID-19 infection to be treated with the antiviral On top of patients who are undergoing invasive medical ventilation, the compassionate use recommendation from EMA now covers […]

FDA OK’s AZ & Merck’s Lynparza Plus Bevacizumab in HRD-Positive Ovarian Cancer

Country: UNITED STATES | Region: NORTH AMERICA | Type: Drug Approval | Keywords: #astrazeneca #fda #merck PRICENTRIC BRIEF: Lynparza (olaparib) in combination with bevacizumab (branded as Avastin) was approved by the US Food and Drug Administration (FDA) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and […]

EVERSANA to present at the Virtual ISPOR 2020

Analyze, Deliver, Measure and Communicate Value at Every Stage of the Product Lifecycle. Join our experts LIVE during one of the 4 presentations to get a deeper understanding of key issues impacting our value-driven healthcare environment. Request a time to meet.     PANEL: ARE EXISTING REGULATORY EVIDENCE STANDARDS ADEQUATE FOR INFORMING DECISIONS ON MEDICAL […]

Biosimilars Saved Spain 2,400 Million Euros Between 2009 and 2020

Country: SPAIN | Region: EUROPE | Type: Biosimilar | Keywords: #inflammatorydiseases #monoclonalantibodies #oncology #regulation #sefh PRICENTRIC BRIEF: The Spanish Society of Hospital Pharmacists (SEFH) calculated that Spain has saved more than 2,400 million euros between 2009 and 2020 through the introduction of biosimilars for the treatment of inflammatory diseases and cancer In the article, published in the May/June issue of the journal Farmacia Hospitalaria, Dr. Miguel Ángel Calleja, former […]

Brazil in Talks to Gain Access to Gilead’s Remdesivir

Country: BRAZIL | Region: SOUTH AMERICA | Type: Regulation | Keywords: #anvisa #compassionateuse #covid-19 #gilead #patientaccess #remdesivir PRICENTRIC BRIEF: The National Health Surveillance Agency (ANVISA) is in talks with Gilead to guarantee quick access to the antiviral Remdesivir for the treatment of patients who are hospitalized with COVID-19 ANVISA already has mechanisms, including consent to use in a health care program and priority registration, prepared for Remdesivir pending initial […]

UK National Clinical Trial Initiative Could Fast-Track COVID-19 Treatments

Country: UNITED KINGDOM | Region: EUROPE | Type: Regulation | Keywords: #clinical #covid19 #dhsc #national #trial #uk PRICENTRIC BRIEF: The initiative will accelerate the development of new drugs for patients hospitalised with COVID-19, reducing the time taken to set up clinical studies for new therapies from months to weeks Six potential drugs will initially enter the program, with the first of these beginning phase 2 studies across the UK […]

Pricentric Insights: China’s Interim Measures for NRDL, BMI Administration

Region: ASIA & SOUTH PACIFIC | Type: Policy | Keywords: #bmi #copay #drugapprovals #healthinsurance #negotiations #nhsa #nrdl #pricingandreimbursement #regulation PRICENTRIC BRIEF: The National Healthcare Security Administration (NHSA) has released a draft proposal on interim measures surrounding the administration of medicines under the Basic Medical Insurance (BMI) scheme, in which China addresses the management of the national reimbursed drug list (NRDL), including the eligibility for the inclusion or exclusion of […]

EVERSANA™ appoints Kelly Baker to Chief Financial Officer

Seasoned financial executive to shepherd global growth and scale of commercial service platform CHICAGO – May 4, 2020 – EVERSANA™, the leading independent provider of global commercial services to the life sciences industry, today announced the appointment of Kelly Baker to Chief Financial Officer (CFO). Baker will direct the company’s financial excellence and lead the […]